Email updates

Keep up to date with the latest news and content from JTM and BioMed Central.

Open Access Research

Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival

Loris Bertazza12, Simone Mocellin1*, Alberto Marchet1, Pierluigi Pilati1, Joseph Gabrieli1, Romano Scalerta1 and Donato Nitti1

Author Affiliations

1 Department of Oncological & Surgical Sciences, Section of Clinica Chirurgica 2, University of Padova, via Giustiniani 2, 35128, Padua, Italy

2 Istituto Oncologico Veneto IRCCS, via Gattamelata 64, 35128, Padua, Italy

For all author emails, please log on.

Journal of Translational Medicine 2009, 7:111  doi:10.1186/1479-5876-7-111

Published: 22 December 2009

Abstract

Background

The detection of circulating tumor cells (CTC) is considered a promising tool for improving risk stratification in patients with solid tumors. We investigated on whether the expression of CTC related genes adds any prognostic power to the TNM staging system in patients with gastric carcinoma.

Methods

Seventy patients with TNM stage I to IV gastric carcinoma were retrospectively enrolled. Peripheral blood samples were tested by means of quantitative real time PCR (qrtPCR) for the expression of four CTC related genes: carcinoembryonic antigen (CEA), cytokeratin-19 (CK19), vascular endothelial growth factor (VEGF) and Survivin (BIRC5).

Results

Gene expression of Survivin, CK19, CEA and VEGF was higher than in normal controls in 98.6%, 97.1%, 42.9% and 38.6% of cases, respectively, suggesting a potential diagnostic value of both Survivin and CK19. At multivariable survival analysis, TNM staging and Survivin mRNA levels were retained as independent prognostic factors, demonstrating that Survivin expression in the peripheral blood adds prognostic information to the TNM system. In contrast with previously published data, the transcript abundance of CEA, CK19 and VEGF was not associated with patients' clinical outcome.

Conclusions

Gene expression levels of Survivin add significant prognostic value to the current TNM staging system. The validation of these findings in larger prospective and multicentric series might lead to the implementation of this biomarker in the routine clinical setting in order to optimize risk stratification and ultimately personalize the therapeutic management of these patients.